Sugi Predict

Sugi Predict / Targets / UHRF1

UHRF1

E3 ubiquitin-protein ligase UHRF1 · Q96T88 · UHRF1 on Sugi Atlas →

5,175 patent compounds predicted against UHRF1, 2,936 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1494905 SCHEMBL1494905 0.77 2/20
SCHEMBL1494731 SCHEMBL1494731 0.69 2/20
SCHEMBL1494800 SCHEMBL1494800 0.68 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4888175) 0.67 2/20
SCHEMBL3752174 SCHEMBL3752174 0.66 2/20
SCHEMBL3122139 SCHEMBL3122139 0.66 2/20
SCHEMBL105276 SCHEMBL105276 0.65 2/20
SCHEMBL1494835 SCHEMBL1494835 0.65 2/20
SCHEMBL1495163 SCHEMBL1495163 0.63 2/20
SCHEMBL3757868 SCHEMBL3757868 0.63 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL5953779) 0.63 2/20
SCHEMBL3753082 SCHEMBL3753082 0.62 2/20
SCHEMBL3751269 SCHEMBL3751269 0.62 2/20
SCHEMBL1494752 SCHEMBL1494752 0.61 2/20
SCHEMBL3752307 SCHEMBL3752307 0.60 2/20
SCHEMBL3751792 SCHEMBL3751792 0.59 2/20
SCHEMBL398960 SCHEMBL398960 0.59 2/20
SCHEMBL3759398 SCHEMBL3759398 0.59 2/20
SCHEMBL3800758 SCHEMBL3800758 0.58 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL396290) 0.58 2/20

Clinical trials — most relevant to UHRF1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer PHASE1ACTIVE_NOT_RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Using Mobile Technology to Improve Self-Regulation nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria nanCOMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Establishment of a Prospective Clinical-biological Database nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a UHRF1 binder may also engage these)

ProteinNameSimilarity
Q7TPK1 — 1.000 Q7TPK1 →
Q7TMI3 — 1.000 Q7TMI3 →
A7E320 — 1.000 A7E320 →
Q8VDF2 — 1.000 Q8VDF2 →
E7EZF3 — 1.000 E7EZF3 →
F6UA42 — 0.999 F6UA42 →
Q96PU4 — 0.997 Q96PU4 →
B6CHA3 — 0.997 B6CHA3 →
Q8WML3 — 0.990 Q8WML3 →
Q8LPU5 — 0.990 Q8LPU5 →
Q12756 — 0.990 Q12756 →
DHX29 ATP-dependent RNA helicase DHX29 0.990 landscape →
A3KFM7 — 0.989 A3KFM7 →
CHD4 Chromodomain-helicase-DNA-binding protein 4 0.989 landscape →
Q6C710 — 0.989 Q6C710 →
Q9ARI6 — 0.989 Q9ARI6 →
Q9AXT8 — 0.989 Q9AXT8 →
Q5XI06 — 0.989 Q5XI06 →
KDM4B Lysine-specific demethylase 4B 0.989 landscape →
Q9AWM8 — 0.989 Q9AWM8 →
A0A0R4IKJ1 — 0.989 A0A0R4IKJ1 →
Q61T02 — 0.989 Q61T02 →
ASH2L Set1/Ash2 histone methyltransferase complex subunit ASH2 0.989 landscape →
Q08BS4 — 0.989 Q08BS4 →
KAT8 Histone acetyltransferase KAT8 0.989 landscape →
Q6PDQ2 — 0.989 Q6PDQ2 →
D3ZA12 — 0.989 D3ZA12 →
Q5TKR9 — 0.988 Q5TKR9 →
Q9C813 — 0.988 Q9C813 →
KDM5B Lysine-specific demethylase 5B 0.988 landscape →